236 related articles for article (PubMed ID: 29739463)
41. Public Mistrust of the U.S. Health Care System's Profit Motives: Mixed-Methods Results from a Randomized Controlled Trial.
Richmond J; Powell W; Maurer M; Mangrum R; Gold MR; Pathak-Sen E; Yang M; Carman KL
J Gen Intern Med; 2017 Dec; 32(12):1396-1402. PubMed ID: 28875447
[TBL] [Abstract][Full Text] [Related]
42. Public engagement in priority-setting: results from a pan-Canadian survey of decision-makers in cancer control.
Regier DA; Bentley C; Mitton C; Bryan S; Burgess MM; Chesney E; Coldman A; Gibson J; Hoch J; Rahman S; Sabharwal M; Sawka C; Schuckel V; Peacock SJ
Soc Sci Med; 2014 Dec; 122():130-9. PubMed ID: 25441325
[TBL] [Abstract][Full Text] [Related]
43. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
44. Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable.
Levy AR; Gagnon YM
Healthc Pap; 2002; 3(1):32-7; discussion 87-94. PubMed ID: 12811108
[TBL] [Abstract][Full Text] [Related]
45. Centralized drug review processes: are they fair?
Mitton CR; McMahon M; Morgan S; Gibson J
Soc Sci Med; 2006 Jul; 63(1):200-11. PubMed ID: 16427728
[TBL] [Abstract][Full Text] [Related]
46. Citizens' Perspectives on Disinvestment from Publicly Funded Pathology Tests: A Deliberative Forum.
Street JM; Callaghan P; Braunack-Mayer AJ; Hiller JE
Value Health; 2015 Dec; 18(8):1050-6. PubMed ID: 26686790
[TBL] [Abstract][Full Text] [Related]
47. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
Morgan SG; Agnew JD; Barer ML
Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
[TBL] [Abstract][Full Text] [Related]
48. Evaluating reference-based pricing: initial findings and prospects.
Narine L; Senathirajah M; Smith T
CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052
[TBL] [Abstract][Full Text] [Related]
49. Informed consent in biobank research: a deliberative approach to the debate.
Secko DM; Preto N; Niemeyer S; Burgess MM
Soc Sci Med; 2009 Feb; 68(4):781-9. PubMed ID: 19095337
[TBL] [Abstract][Full Text] [Related]
50. Can Severity Outweigh Smaller Numbers? A Deliberative Perspective from Canada.
Magalhaes M
Value Health; 2018 May; 21(5):532-537. PubMed ID: 29753349
[TBL] [Abstract][Full Text] [Related]
51. Pricing and Paying for Cancer Drugs: Policy Options for Fixing A Broken System.
Hyman DA; Silver C
Cancer J; 2020; 26(4):298-303. PubMed ID: 32732672
[TBL] [Abstract][Full Text] [Related]
52. Psychogeriatric care: building rural community capacity.
Morrow MH; Hemingway D; Grant J; Jamer B
Rural Remote Health; 2012; 12():1971. PubMed ID: 22650617
[TBL] [Abstract][Full Text] [Related]
53. Priority setting in the provincial health services authority: survey of key decision makers.
Teng F; Mitton C; Mackenzie J
BMC Health Serv Res; 2007 Jun; 7():84. PubMed ID: 17565691
[TBL] [Abstract][Full Text] [Related]
54. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
55. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
56. Bedside rationing by general practitioners: a postal survey in the Danish public healthcare system.
Lauridsen SM; Norup M; Rossel P
BMC Health Serv Res; 2008 Sep; 8():192. PubMed ID: 18808694
[TBL] [Abstract][Full Text] [Related]
57. Factors affecting engagement between academic faculty and decision-makers: learnings and priorities for a school of public health.
Jessani NS; Siddiqi SM; Babcock C; Davey-Rothwell M; Ho S; Holtgrave DR
Health Res Policy Syst; 2018 Jul; 16(1):65. PubMed ID: 30045730
[TBL] [Abstract][Full Text] [Related]
58. Health technology adoption and the politics of governance in the UK.
Milewa T
Soc Sci Med; 2006 Dec; 63(12):3102-12. PubMed ID: 16982120
[TBL] [Abstract][Full Text] [Related]
59. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
Chabot I; Rocchi A
Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
[TBL] [Abstract][Full Text] [Related]
60. The costs of change: direct medical costs of solid organ transplantation in British Columbia, Canada, 1995-2003.
Levy AR; Sobolev B; James D; Barrable W; Clarke-Richardson P; Sullivan SD; Keown PA; Chung S; Straatman L; Levy RD
Value Health; 2009; 12(2):282-92. PubMed ID: 18783395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
